companies equity الخاص تoinvest متزايدًا في الرعاية القلبية الأيضية (CMD) حيث تكتسب أدوية GLP-1 لإنقاص الوزن زخماً وت转移 الرعاية القلبية من المستشفيات إلى بيئة العيادات. CMD يشمل أمراض القلب، والسكتات الدماغية، والسكري، وارتفاع ضغط الدم، و(ROOT) الكبد. Six notable deals include General Catalyst's $450m funding for Function Health، a personalized health testing platform in Austin، Texas. ArchiMed completed a $1.1bn take-private of Esperion Therapeutics، a biopharma company in Ann Arbor، Michigan focused on cardiometabolic therapies. THL Partners-backed Headlands Research acquired Clinical Trials Research، a Sacramento-based clinical trial network. SK Capital-backed Spectrum Vascular acquired Piccolo Medical، a San Francisco medtech firm developing vascular navigation technology. Resonetics bought Arcline-backed Resolution Medical، a Minnesota-based device manufacturer. River Glade Capital's Dynamic Access acquired Picc Stat، a Dallas-based vascular access services provider.
PE firms see opportunities in CMD due to the growing affordability of GLP-1 weight-loss drugs، which improve obesity treatment—a key risk factor for heart disease and diabetes—and shifts toward outpatient care that create demand for specialized providers and technologies.
المصدر: PE Hub · لخّصه HeadlinesBriefing